Clinical Trial Search

Phase 3 N=588 Efficacy and Safety of LCZ696 in Comparison to Olmesartan in Elderly Patients With Essential Hypertension

Essential Hypertension

Primary: Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP) — -22.71; -16.11 mmHg

Novartis Pharmaceuticals Results Aug 2015 1.5% serious AE View details

Phase 3 N=508 Open-Label Long-Term Safety and Efficacy Study of Fixed Dose Combination of Nifedipine Gastrointestinal Therapeutic System and Candesartan Cilexetil in Subjects With Moderate to Severe Essential Hypertension

Hypertension

Primary: Number of Subjects With All Treatment-emergent Adverse Events (TEAEs) and Drug-related TEAEs up to Week 28 — 390; 230 Subjects

Bayer Results Aug 2015 2.9% serious AE View details

Phase 3 N=72 Safety and Efficacy the Medigus SRS Endoscopic Stapling System in Gastroesophageal Reflux Disease (GERD)

Gastroesophageal Reflux Disease (GERD)

Primary: Percentage of Participants With >= 50% Improvement in GERD Health Related Quality of Life (GERD-HRQL - Velanovich) Score — 73 percentage of total participants

Aviel Roy-Shapira, M.D. Results Aug 2015 13.9% serious AE View details

Phase 3 N=424 A Study of Avastin (Bevacizumab) in Combination With Herceptin (Trastuzumab)/Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.

Breast Cancer

Primary: Progression Free Survival (PFS) — 13.7; 16.5 months — p=0.0775

Hoffmann-La Roche Results Aug 2015 32.1% serious AE View details

Phase 3 N=287 Compare D961H 20 mg Bid and 20 mg qd in Patients With Refractory Reflux Esophagitis (Inflammation of Lower Esophagus)

Refractory Reflux Esophagitis

Primary: Percentage of Participants With Healing of RE Who Were Graded "O" at Week 8 Out of Participants Who Were Graded "A" to "D" at Baseline According to Los Angeles…

AstraZeneca Results Aug 2015 1.4% serious AE View details

Phase 3 N=41 A Study of Bonviva/Boniva (Ibandronate) in Biphosphonate-Naïve Women With Post-Menopausal Osteoporosis

Post Menopausal Osteoporosis

Primary: Percent Change From Baseline in Mean Lumbar Spine Bone Mineral Density (BMD) at Month 12 — 5.67 percent change — p=<0.0005

Hoffmann-La Roche Results Aug 2015 22.5% serious AE View details

Phase 3 N=95 A Long Term Study To Evaluate The Safety, Tolerability And Efficacy Of CP-690,550 In Patients With Moderate To Severe Plaque Psoriasis And/Or Psoriatic Arthritis

Psoriasis

Primary: Percentage of Participants With a Psoriasis Area and Severity Index 75 (PASI75) Response at Week 16 — 62.8; 72.7; 67.8 Percentage of participants

Pfizer Results Aug 2015 6.4% serious AE View details

Phase 3 N=457 An Efficacy, Pharmacokinetics, Safety and Tolerability Study of TMC435 as Part of a Treatment Regimen for Hepatitis C-Infected Patients

Hepatitis C, Chronic

Primary: Percentage of Participants With Sustained Virologic Response 12 Weeks After End of Study Drug Treatment (SVR12) — 75.7; 88.9; 90.8 Percentage of participants

Janssen R&D Ireland Results Aug 2015 4.2% serious AE View details

Phase 3 N=32 Safety and Tolerability and Efficacy of LCZ696 in Japanese Hypertensive Patients With Renal Dysfunction

Hypertension With Renal Dysfunction

Primary: Percentage of Participants With Reported Adverse Events (Total Adverse Events, Serious Adverse Events and Death) — 31.3; 0; 27.8; 43.8 Percentage of participants

Novartis Pharmaceuticals Results Aug 2015 0.0% serious AE View details

Phase 3 N=451 Inhaled Nitric Oxide (INO) for the Prevention of Bronchopulmonary Dysplasia (BPD) in Preterm Infants

Bronchopulmonary Dysplasia

Primary: Survival Without BPD at 36 Weeks — 80; 70; 149; 152 participants — p=0.427

Mallinckrodt Results Aug 2015 45.7% serious AE View details

Phase 3 N=247 Rotigotine Versus Placebo As Double Blind Study To Evaluate The Efficacy In Early Stage Idiopathic Parkinson's Disease Patients

IDIOPATHIC PARKINSON'S DISEASE

Primary: Change in the Sum of the Score From the Activities of Daily Living (ADL) Scale and Motor Examination in the Unified Parkinson's Disease Rating Scale (UPDRS) (Parts…

UCB Pharma Results Aug 2015 2.8% serious AE View details

Phase 3 N=75 Efficacy, Safety and Immunogenicity Study of Recombinant Human C1 Inhibitor for the Treatment of Acute HAE Attacks

Hereditary Angioedema

Primary: Time to Beginning of Relief of Symptoms — 90; 152 minutes

Pharming Technologies B.V. Results Aug 2015 1.4% serious AE View details

Phase 3 N=1,561 Safety and Immunogenicity of Two Trivalent Subunit Influenza Vaccines in Healthy Adult Subjects

Prophylaxis: Influenza

Primary: Immunologic Equivalence of 3 Consecutive Influenza Vaccine (TIVc) Production Lots. — 667; 738; 655; 466 Titers

Novartis Vaccines Results Aug 2015 0.1% serious AE View details

Phase 3 N=3,154 Dexamethasone Compared With Prednisone During Induction Therapy and Methotrexate With or Without Leucovorin During Maintenance Therapy in Treating Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia · Adult B Acute Lymphoblastic Leukemia · Childhood B Acute Lymphoblastic Leukemia

Primary: Comparison of the Increase in Cure Rate of High Risk ALL Without Causing More Serious Side Effects Between Interventions — 83.2; 81.6; 69.1; 91.2 percentage of…

Children's Oncology Group Results Aug 2015 11.1% serious AE View details

Phase 3 N=1,161 Efficacy and Safety of LCZ696 in Comparison to Olmesartan in Japanese Patients With Essential Hypertension

Essential Hypertension

Primary: Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP) — -18.21; -20.18; -13.20 mmHg

Novartis Pharmaceuticals Results Aug 2015 0.8% serious AE View details